Kiniksa Pharmaceuticals Ltd. Class A Stock News
$37.10
0.24%
yesterday
Nasdaq,
Sep 12, 10:00 pm CET
Kiniksa Pharmaceuticals Ltd. Class A Stock News
Neutral
Seeking Alpha
●
9 days ago
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Citi's Biopharma Back to School Conference September 3, 2025 9:00 AM EDT Company Participants Sanj Patel - CEO & Chairman of the Board Ross Moat - Executive VP & Chief Commercial Officer John Paolini - Executive VP & Chief Medical Officer Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoff...
Neutral
GlobeNewsWire
●
15 days ago
LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in September:
Neutral
Investors Business Daily
●
about one month ago
A good medical stock can help diversify a portfolio. This particular name is testing a fresh entry as funds pile in.
Neutral
Seeking Alpha
●
about 2 months ago
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q2 2025 Earnings Call July 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Officer Mark A. Ragosa - Senior VP & CFO Ross Michael Moat - Executive VP & Chief Commercial Officer Sanj K.
Neutral
GlobeNewsWire
●
about 2 months ago
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $625 - $640 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected in 2H 2026 – – Cash balance increased by $39.4 million in Q2 2025 to $307.8 million – – Conference call and w...
Neutral
GlobeNewsWire
●
about 2 months ago
LONDON, July 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 financial results and recent portfolio execution.
Positive
The Motley Fool
●
2 months ago
Explore the exciting world of Kiniksa Pharmaceuticals (KNSA 0.99%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Positive
Investors Business Daily
●
2 months ago
Biotech stock Kiniksa soared after first-quarter results on April 29. Shares are near a buy point of 28.15.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
